1505. Efficacy of Influenza and Pneumococcal Vaccination In Preventing COPD Exacerbation
Session: Poster Abstract Session: Pneumococcal Immunization in Adults
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • vaccine poster, IDSA.pdf (134.1 kB)
  • Background: Common causes of exacerbations in chronic obstructive airway disease (COPD) are due to infections by respiratory viruses and bacteria. Influenza vaccine and pneumococcal vaccine have demonstrated decrease in infective exacerbations in this population.

    Methods: In this prospective study over 2 years, 146 COPD patients confirmed by spirometry in accordance with GOLD criteria and who received both influenza and pneumococcal polysaccharide vaccine were compared with 146 unvaccinated controls. Number of acute exacerbations, hospitalizations, ICU admissions, need for invasive mechanical ventilation, mortality difference for 1 year following vaccination were compared.

    Results:

    In vaccinated group there was statistically significant reduction in number of exacerbations of COPD, requirement of hospitalization, ICU admissions and mortality which is depicted in the table. Requirement of mechanical ventilation was higher among cases compared to controls more so among GOLD 3 and 4, which is statistically significant.

    COPD

    Vaccinated

    Unvaccinated

    P value

    Number of exacerbations

    3.23

    4.5

    <0.001

    Hospitalization requirement

    36.3%

    50%

    0.018

    ICU admissions

    17.8%

    30.1%

    0.014

    Requirement of mechanical ventilation

    14.2%

    6.2%

    0.021

    Mortality

    3

    17

    0.01

    Subgroup analysis showed a significantly less hospitalization, ICU admission and mortality among vaccinated belonging to GOLD 1 and GOLD 2 as compared to matched controls. Also more exacerbations, hospitalizations, ICU admissions and mortality were observed in GOLD 3 and GOLD 4 who were not vaccinated. But this difference was not statistically significant.

    Conclusion: Overall there was significantly lesser number of exacerbations, hospitalizations, ICU admissions, requirement of mechanical ventilation and mortality among vaccinated group as compared to controls. Subgroup analysis showed a significant benefit from vaccination in COPD GOLD 1 and 2.

    Azharul Haque, MBBS1, Azeez Ameer, MD1, Rajalakshmi Ananthanarayanan, MBBS, DNB2 and Arjun Padmanabhan, MD1, (1)Pulmonary Medicine, Kerala Institute of Medical Sciences, Trivandrum, India, (2)Infectious Diseases, Kerala Institute of Medical Sciences, Trivandrum, India

    Disclosures:

    A. Haque, None

    A. Ameer, None

    R. Ananthanarayanan, None

    A. Padmanabhan, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.